X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -3.4 27.7 - View Chart
P/BV x 0.1 5.3 2.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1261,044 12.1%   
Low Rs61818 7.5%   
Sales per share (Unadj.) Rs301.8298.6 101.1%  
Earnings per share (Unadj.) Rs-24.957.2 -43.4%  
Cash flow per share (Unadj.) Rs2.558.4 4.4%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs293.3249.5 117.6%  
Shares outstanding (eoy) m12.3422.72 54.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 9.9%   
Avg P/E ratio x-3.816.3 -23.1%  
P/CF ratio (eoy) x36.715.9 230.5%  
Price / Book Value ratio x0.33.7 8.5%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,15421,157 5.5%   
No. of employees `0000.90.5 188.0%   
Total wages/salary Rs m393400 98.3%   
Avg. sales/employee Rs Th4,026.113,787.4 29.2%   
Avg. wages/employee Rs Th425.0813.0 52.3%   
Avg. net profit/employee Rs Th-331.82,643.3 -12.6%   
INCOME DATA
Net Sales Rs m3,7246,783 54.9%  
Other income Rs m23353 6.4%   
Total revenues Rs m3,7477,136 52.5%   
Gross profit Rs m3951,617 24.4%  
Depreciation Rs m33827 1,271.8%   
Interest Rs m3546 6,441.8%   
Profit before tax Rs m-2751,938 -14.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m32632 5.0%   
Profit after tax Rs m-3071,301 -23.6%  
Gross profit margin %10.623.8 44.5%  
Effective tax rate %-11.532.6 -35.2%   
Net profit margin %-8.219.2 -43.0%  
BALANCE SHEET DATA
Current assets Rs m2,6386,984 37.8%   
Current liabilities Rs m2,3052,056 112.1%   
Net working cap to sales %8.972.6 12.3%  
Current ratio x1.13.4 33.7%  
Inventory Days Days13599 136.4%  
Debtors Days Days4624 193.5%  
Net fixed assets Rs m4,871244 1,993.8%   
Share capital Rs m123227 54.3%   
"Free" reserves Rs m3,4965,441 64.2%   
Net worth Rs m3,6195,668 63.9%   
Long term debt Rs m1,37425 5,497.6%   
Total assets Rs m7,5097,901 95.0%  
Interest coverage x0.2353.3 0.1%   
Debt to equity ratio x0.40 8,610.0%  
Sales to assets ratio x0.50.9 57.8%   
Return on assets %0.616.5 3.8%  
Return on equity %-8.522.9 -37.0%  
Return on capital %1.634.0 4.6%  
Exports to sales %00.2 0.0%   
Imports to sales %13.936.3 38.2%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m5172,465 21.0%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m5172,677 19.3%   
Net fx Rs m-517-2,662 19.4%   
CASH FLOW
From Operations Rs m514923 55.7%  
From Investments Rs m-123317 -38.8%  
From Financial Activity Rs m-387-481 80.5%  
Net Cashflow Rs m4759 0.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   J.B.CHEMICALS  SUVEN LIFE  IPCA LABS  CADILA HEALTHCARE  ALEMBIC LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 297 Points Higher; Energy and Realty Stocks Witness Buying(Closing)

Share markets in India continued their momentum during closing hours and ended the day on a positive note. Sectoral indices were trading on a positive note, with stocks in the energy sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS